Loading clinical trials...

A Study to Evaluate the Drug Interaction of ASP015K and Tacrolimus | Clinical Trials | Clareo Health

COMPLETEDPHASE1

A Study to Evaluate the Drug Interaction of ASP015K and Tacrolimus

A Phase 1, Open Label, Drug Interaction Study of the Pharmacokinetics of ASP015K and Tacrolimus After Separate and Concomitant Administration to Healthy Adult Subjects

NCT01190670•Astellas Pharma Inc

View on ClinicalTrials.gov

Summary

The objective of the study is to characterize the effect of multiple doses of ASP015K on the pharmacokinetics of a single oral dose or a single intravenous (IV) dose of tacrolimus.

Detailed Description

This is a 2-part study. Part 1 is a 2-sequence, drug interaction study to determine the effect of two different ASP015K doses on the pharmacokinetics of oral tacrolimus. Part 2 is a 1-sequence drug interaction study to determine the effect of the higher dose ASP015K on the pharmacokinetics of IV tacrolimus.

Eligibility

Age

18 - 55 years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•Subject weighing at least 45kg and body mass index (BMI) of 18-32 kg/m2, inclusive
•If female, subject is at least 2 years post menopausal or is surgically sterile per documentation provided by a third party medical professional and the subject is not pregnant as documented by a negative serum pregnancy test
•If male, subject agrees to sexual abstinence, is surgically sterile, or is using a medically acceptable method to prevent pregnancy during the study period
•12-lead ECG is normal or if abnormal, the abnormality is not clinically significant
•Clinical laboratory test results are within normal limits or not clinically significant
•Medically healthy, with no clinically significant medical history or abnormalities

Exclusion Criteria

•History of any clinically significant disorder, disease or malignancy excluding non-melanoma skin cancer
•Recent history (within 6 months) of drug or alcohol abuse or positive urine screen for drugs of abuse/illegal drugs
•Treatment with prescription drugs or complementary and alternative medicines (CAM) within 14 days prior to study drug administration, or over the counter medication within 1 week prior to study drug administration
•A symptomatic, viral, bacterial or fungal infection within 1 week prior to clinic check-in
•Positive test for hepatitis C antibody, or positive test for hepatitis B surface antigen (HBsAg)
•History of human immunodeficiency virus (HIV) antibody
•Positive tuberculosis (TB) skin test or Quantiferon Gold test
•Vaccinated within the last 30 days prior to study drug administration
•Received an experimental agent within 30 days or five half-lives, whichever is longer, prior to study drug administration
•Any significant blood loss, donated one unit (450 mL) of blood or more, or received a transfusion of any blood or blood products within 60 days or donated plasma within 7 days prior to clinic admission
+1 more criteria

Locations (1)

Honolulu, Hawaii, United States

Key Dates

Start Date

July 1, 2010

Primary Completion Date

September 1, 2010

Completion Date

September 1, 2010

Last Updated

October 14, 2010

Enrollment

ACTUAL participants

Conditions

HealthyPharmacokinetics of ASP015K and Tacrolimus

Interventions

Tacrolimus

DRUG

ASP015K

DRUG

Research Into the Safety of a New Agent (VT-5006) in People With and Without Parkinson's Disease

NCT07310264

Healthy Volunteers (HV)Parkinson's Disease (PD)

View study

RECRUITINGNA

A New Portable Device for Non-invasive Ventilatory Support

NCT06716502

HealthyRespiratory Disease

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: October 14, 2010Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Study to Evaluate the Drug Interaction of ASP015K and Tacrolimus

Inclusion Criteria

Exclusion Criteria

Research Into the Safety of a New Agent (VT-5006) in People With and Without Parkinson's Disease

A New Portable Device for Non-invasive Ventilatory Support

Fecal Microbiota Transplantation for Patients With Autism Spectrum Disorder.

Collection of Data and Samples From Healthy Donors for Use in Translational Research

Turkish Validity and Reliability Study of PRevention of Toxic Chemicals in the Environment for Children Tool

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single- and Multiple-Ascending Doses and Food Effect of BGB-45035 in Healthy Participants and in Adults With Autoimmune Dermatological Diseases